LCC Reviewers Required

The ‘Let’s Communicate Cancer’ working group have a great opportunity for pharmacists to become involved in the review of the ‘Let’s communicate cancer’ training modules.

 

‘Let’s communicate cancer’ is an extensive resource for all health professionals on many aspects of cancer care. The resource includes information on cancer prevention, diagnosis, treatments, and how to better support patients undergoing cancer treatment. Of the five training modules, four will need to be reviewed in the current update:

 

  • Module 1: Early diagnosis and prevention
  • Module 2: What is cancer
  • Module 3: Treatment of cancer
  • Module 4: Supporting your patients with cancer

 

Who are we looking for?

 

For the update, we are looking for a number of experienced pharmacists to review the eLearning content which includes PowerPoint presentations, quizzes, PDFs and videos. If you have a minimum of 3 years’ experience practicing in oncology, or alternatively, if you are a community pharmacist with an interest in oncology we would love to hear from you.

 

How to apply?

 

If you would like to get involved please send us a brief statement (roughly 300 words) of the skills and experience you have which would be beneficial in the review of the modules. Please also include your current role and place of work.

Applications should be sent to [email protected]. Please note, applications will close on 29th March 2024 and we will let candidates know the outcome by 22nd April 2024.

 

Thank you!

We understand everyone is under increased pressure at the moment and the reviewer will be remunerated for their valuable time. We aim to have the review completed by the end of May.

Thank you for considering this opportunity and we look forward to hearing from you!

 

Best wishes,

Jackie Lewis and Jennifer McClintick

Latest News

By BOPA Executive Committee on 25th April 2025

NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer at high risk of recurrence in adults.

BOPA have been involved with the following NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer…

Read article
By BOPA IO SAG on 23rd April 2025

Toolkit for Immunotherapy IV to SC switch

Dear all, In the coming months, an increasing number of products traditionally administered intravenously are expected to become available for subcutaneous administration. This shift offers enhanced flexibility for patients; however,…

Read article
By BOPA E&T subcommittee on 17th April 2025

The BOPA Cancer Consultant Pharmacist Credentialing Support Series is back

BOPA are holding a nine month supportive webinar series for pharmacists who are credentialing as consultant pharmacists with the RPS. Join in this relaxed forum to discuss about your portfolio…

Read article
By BOPA research subcommittee on 17th April 2025

Celebration of BOPA member’s recent publications

We are delighted to share that so many of our members have had manuscripts published recently. Here are some that we are aware of but if there are others then…

Read article